163 related articles for article (PubMed ID: 9547674)
1. An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92.
Schiller JH; Neuberg D; Burns D; Ritch P; Larson M; Levitt M; Dutcher J
Invest New Drugs; 1997; 15(4):319-24. PubMed ID: 9547674
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
Wadler S; Schwartz EL; Haynes H; Rameau R; Quish A; Mandeli J; Gallagher R; Hallam S; Fields A; Goldberg G; McGill F; Jennings S; Wallach RC; Runowicz CD
Cancer; 1997 Apr; 79(8):1574-80. PubMed ID: 9118041
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of all-trans-retinoic acid and alpha-interferon in patients with advanced non-small cell lung cancer.
Athanasiadis I; Kies MS; Miller M; Ganzenko N; Joob A; Marymont M; Rademaker A; Gradishar WJ
Clin Cancer Res; 1995 Sep; 1(9):973-9. PubMed ID: 9816069
[TBL] [Abstract][Full Text] [Related]
9. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
Boorjian SA; Milowsky MI; Kaplan J; Albert M; Cobham MV; Coll DM; Mongan NP; Shelton G; Petrylak D; Gudas LJ; Nanus DM
J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529
[TBL] [Abstract][Full Text] [Related]
10. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study.
Gill PS; Espina BM; Moudgil T; Kidane S; Esplin JA; Tulpule A; Levine AM
Leukemia; 1994; 8 Suppl 3():S26-32. PubMed ID: 7808021
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
13. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.
Weiss GR; Liu PY; Alberts DS; Peng YM; Fisher E; Xu MJ; Scudder SA; Baker LH; Moore DF; Lippman SM
Gynecol Oncol; 1998 Dec; 71(3):386-90. PubMed ID: 9887236
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
15. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J
Eur J Cancer Clin Oncol; 1986 Jun; 22(6):685-9. PubMed ID: 3091371
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
18. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]